Tag: OUNJ
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
Significantly lower risks seen for those receiving GLP-1 receptor agonists compared with other antidiabetic drugs
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss
Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement
Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively
